Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-06-06 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于全资子公司回购控股子公司股权暨完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the repurchase of controlling shares in a subsidiary by a wholly-owned subsidiary and the completion of related business registration changes. It details the transaction overview, progress, and official registration updates. The document is relatively short (1483 characters) and focuses on a specific corporate transaction and its completion, rather than providing comprehensive financial data or detailed financial statements. It does not contain financial results, earnings data, or management discussion of financial performance. It is not a full report but an announcement of a corporate action and its completion. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share repurchases or changes in ownership structure.
2023-06-06 Chinese
2023年第一季度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of a 2023 first quarter equity distribution plan by Beijing Kangle Weishi Biotechnology Co., Ltd. It details the equity distribution scheme, tax deductions, record dates, ex-dividend dates, shareholders entitled, and share changes. The document is relatively short (2104 characters) and focuses on dividend and share distribution details rather than presenting full financial statements or comprehensive financial performance. It is not an annual or quarterly report, nor a management discussion or earnings release. The content fits the definition of a Notice of Dividend Amount (DIV), as it announces dividend amounts, payment dates, and details for shareholders.
2023-05-16 Chinese
关于全资子公司回购控股子公司股权进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a transaction where a wholly-owned subsidiary repurchases controlling shares of a subsidiary. It details the transaction overview, progress, contract terms, and subsequent steps. The document is relatively short (1935 characters) and focuses on the announcement of the transaction progress rather than providing comprehensive financial data or detailed financial statements. It does not contain financial results, audit opinions, or management discussions typical of annual or interim reports. It is not a call transcript, earnings release, or governance information. The content fits best with a Capital/Financing Update (CAP) as it relates to a financing activity involving share repurchase and ownership changes within subsidiaries. Therefore, the classification is CAP with high confidence.
2023-05-16 Chinese
北京观韬中茂律师事务所关于北京康乐卫士生物技术股份有限公司2023年第六次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedural compliance of a company's 2023 sixth extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data but focuses on the legal validation of the shareholders' meeting process and resolutions. It is not a report of financial results, audit, or management discussion, nor is it a simple announcement or certification. The content aligns with a legal proceedings report related to corporate governance and shareholder meeting legality.
2023-05-14 Chinese
2023年第六次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2023 sixth extraordinary shareholders' meeting of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about the meeting's convening, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The document specifically reports the voting results on several proposals, including approval of the 2023 Q1 audit report, equity distribution plan, and amendments to the company's articles of association. The presence of detailed voting results and the nature of the document as an official announcement of shareholder meeting decisions clearly identifies it as a Declaration of Voting Results & Voting Rights Announcements. The document length is under 5,000 characters and it does not contain the full audit report or financial statements but references them as disclosed elsewhere, so it is not the report itself but the voting results announcement related to those reports.
2023-05-14 Chinese
北京观韬中茂律师事务所关于北京康乐卫士生物技术股份有限公司2022年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2022 Annual General Meeting (AGM) of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the legality and validity of the AGM process, including the notice, attendance, voting results, and compliance with relevant laws and company articles. The document does not contain the actual AGM materials or presentations but serves as a legal confirmation of the AGM procedures and results. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting outcomes and procedural compliance of the AGM.
2023-05-11 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.